ClinicalTrials.gg
CompletedNCT06039579CINNAMONUpdated Sep 30, 2025Results posted

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

A Phase 2 interventional study of VH4004280 and VH4011499 in HIV Infections, sponsored by ViiV Healthcare. Completed at 20 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
138th of 210
44 · median 82
Started
2023
with 9 others
Phase 2
48 of 266
2 open now
Registered
239th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 138th largest by enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2023, is one of 48 in phase 2, and was the 239th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the antiviral activity of orally administered VH4004280 and VH4011499 monotherapy over 10 days in human immunodeficiency virus (HIV-1) infected Treatment-Naïve (TN) participants.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • VH4004280
  • VH4011499
  • Treatment Naïve
  • Phase 2a
  • Monotherapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy (other than -1 infection).
  • Screening cluster of differentiation-4 (CD4+) T-cell count greater than or equal to (≥)200 cells/microliter (µL).
  • Documented HIV-1 infection and Screening plasma HIV-1 RNA ≥3000 copies/milliliter (mL).
  • Treatment-naïve: Defined as no antiretroviral therapy received after the diagnosis of HIV-1 infection. Prior use of oral pre-exposure prophylaxis (PreP) is permitted. Prior use of parenteral PreP is exclusionary.
  • Has (BMI) within the range of 18.5-31.0 kilograms per meter square (kg/m\^2).
  • Participants male at birth must use male condoms and participants female at birth who are of must be using acceptable forms of .
  • Participants capable of giving signed .
  • Participant must be willing and able to start locally accessible and commercially available combination antiretroviral therapy after the monotherapy period.

Exclusion criteria

Exclusion Criteria:

  • Women who are breastfeeding or plan to become pregnant or breast feed during the study.
  • Participants with acute infection.
  • Any evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3 disease.
  • Untreated syphilis infection.
  • Ongoing other than certain localised malignancies.
  • Treatment with immunomodulating agents or any agent with known anti-HIV activity.
  • Has exclusionary psychiatric, hepatic, cardiovascular gastrointestinal, renal condition.
  • Participant having any condition which, in the opinion of the investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to take oral medication.
  • Participants having exclusionary (ECG) findings.
  • Participants who have been exposed to any prohibited medication or vaccine.
  • Participant positive for or .
  • Participants with exclusionary safety laboratory (e.g Grade 3 or greater abnormality).
  • Participants who have positive results for illicit drug use, regular use of drugs of abuse and/or excessive alcohol use.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Part 1a: VH4004280 Dose Level 1

    Participants received a single dose of VH4004280 Dose Level 1 (low concentration) on Day 1 (evaluated for a 10-day period). On Day 11, participants switched to an open-label antiretroviral therapy (ART) up to day 39.

    Drug: VH4004280 · Drug: Antiretroviral therapy

  • Experimental
    Part 1a: VH4004280 Dose Level 2

    Participants received a single dose of VH4004280 Dose Level 2 (medium concentration) on Day 1 (evaluated for a 10-day period). On Day 11, participants switched to an open-label ART up to day 39.

    Drug: VH4004280 · Drug: Antiretroviral therapy

  • Experimental
    Part 2a: VH4004280 pre-specified dose

    Participants received a single pre-specified dose of VH4004280 (high concentration) on Day 1 (evaluated for a 10-day period). On Day 11, participants switched to an open-label ART up to day 39.

    Drug: VH4004280 · Drug: Antiretroviral therapy

  • Placebo comparator
    Matching placebo for VH4004280

    Participants received a matching placebo for VH4004280 on Day 1 (evaluated for a 10-day period). On Day 11, participants switched to an open-label ART up to day 39.

    Drug: VH4004280 Matching Placebo · Drug: Antiretroviral therapy

  • Experimental
    Part 1b: VH4011499 Dose Level 1

    Participants received a single dose of VH4011499 Dose Level 1 (low concentration) on Day 1 and Day 6 (evaluated for a 10-day period). On Day 11, participants had the option to switch to an open-label ART up to day 39.

    Drug: VH4011499 · Drug: Antiretroviral therapy

  • Experimental
    Part 1b: VH4011499 Dose Level 2

    Participants received a single dose of VH4011499 Dose Level 2 (medium concentration) on Day 1 and Day 6 (evaluated for a 10-day period). On Day 11, participants switched to an open-label ART up to day 39.

    Drug: VH4011499 · Drug: VH4011499 Matching Placebo · Drug: Antiretroviral therapy

  • Experimental
    Part 2b: VH4011499 pre-specified dose

    Participants received a single pre-specified dose of VH4011499 (high concentration) on Day 1 and Day 6 (evaluated for a 10-day period). On Day 11, participants switched to an open-label ART up to day 39.

    Drug: VH4011499 · Drug: Antiretroviral therapy

  • Placebo comparator
    Matching placebo for VH4011499

    Participants received a matching placebo for VH4011499 on Day 1 and Day 6 (evaluated for a 10-day period). On Day 11, participants switched to an open-label ART up to day 39.

    Drug: Antiretroviral therapy

Interventions

  • VH4004280 was administered as tablets orally at Day 1.

  • VH4011499 was administered as tablets orally at Day 1 and Day 6.

  • DrugVH4004280 Matching Placebo

    VH4004280 Matching Placebo was administered as tablets orally at Day 1.

  • DrugVH4011499 Matching Placebo

    VH4011499 Matching Placebo was administered as tablets orally at Day 1 and Day 6.

  • DrugAntiretroviral therapy

    Antiretroviral therapy was administered as available and as per investigator's recommendation.

06

What researchers measure

Primary outcomes

  1. Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10

    Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. Maximum change from baseline was calculated by subtracting the baseline value from the post-dose visit value when the plasma HIV-1 RNA reached its minimum level up to Day 11 (inclusive). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. The results were expressed as log10 copies per milliliter (log10 c/mL).

    Time frame: From Baseline (Day 1) and up to Day 11

  2. Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10

    Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. Maximum change from baseline was calculated by subtracting the baseline value from the post-dose visit value when the plasma HIV-1 RNA reached its minimum level up to Day 11 (inclusive). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: From Baseline (Day 1) and up to Day 11

Secondary outcomes

  1. Monotherapy: Number of Participants With Any Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any = occurrence of the event regardless of intensity grade or relation to the study intervention.

    Time frame: From Baseline (Day 1) and up to Day 11

  2. Follow-up: Number of Participants With Any AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any = occurrence of the event regardless of intensity grade or relation to the study intervention.

    Time frame: From Day 11 and up to Day 39

  3. Monotherapy: Number of Participants With AEs by Severity

    Severity was rated according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.

    Time frame: From Baseline (Day 1) and up to Day 11

  4. Follow-up: Number of Participants With AEs by Severity

    Severity was rated according to the DAIDS grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.

    Time frame: From Day 11 and up to Day 39

  5. Monotherapy: Number of Participants With AEs Leading to Study Treatment Discontinuation

    'Discontinuation' of study intervention refers to any participant who has not received all planned doses of study intervention.

    Time frame: From Baseline (Day 1) and up to Day 11

  6. Monotherapy and Follow-up, VH4004280: Change From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin

    Change from Baseline values for liver panel laboratory parameters total bilirubin and direct bilirubin were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.Standard deviation (SD) = 0.0000 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.0000.

    Time frame: At Baseline (Day 1) and at Days 2, 4, 6, 7, 9, 11, 18, 25, 32 and 39

  7. Monotherapy and Follow-up, VH4011499: Change From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin

    Change from Baseline values for liver panel laboratory parameters total bilirubin and direct bilirubin were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value. SD = 0.0000 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.0000.

    Time frame: At Baseline (Day 1) and at Days 2, 4, 6, 7, 9, 11, 18, 25, 32 and 39

  8. Monotherapy and Follow-up, VH4004280: Change From Baseline for Liver Panel Laboratory Parameters - Alanine Aminotransferace (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)

    Change from Baseline values for liver panel laboratory parameters ALT, ALP and AST were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

    Time frame: At Baseline (Day 1) and at Days 2, 4, 6, 7, 9, 11, 18, 25, 32 and 39

  9. Monotherapy and Follow-up, VH4011499: Change From Baseline for Liver Panel Laboratory Parameters - ALT, ALP and AST

    Change from Baseline values for liver panel laboratory parameters ALT, ALP and AST were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

    Time frame: At Baseline (Day 1) and at Days 2, 4, 6, 7, 9, 11, 18, 25, 32 and 39

  10. Monotherapy and Follow-up, VH4004280: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin

    Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.

    Time frame: From Baseline (Day 1) and up to Day 39

  11. Monotherapy and Follow-up, VH4011499: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin

    Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.

    Time frame: From Baseline (Day 1) and up to Day 39

  12. Monotherapy and Follow-up, VH4004280: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - ALT, ALP and AST

    Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.

    Time frame: From Baseline (Day 1) and up to Day 39

  13. Monotherapy and Follow-up, VH4011499: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - ALT, ALP and AST

    Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.

    Time frame: From Baseline (Day 1) and up to Day 39

  14. Monotherapy, VH4004280: Maximum Observed Plasma Drug Concentration (Cmax)

    Cmax is defined as the maximum concentration of the drug in plasma.

    Time frame: After dose administration at Day 1

  15. Monotherapy, VH4011499: Cmax

    Cmax is defined as the maximum concentration of the drug in plasma.

    Time frame: After dose administration at Day 1 and Day 6

  16. Monotherapy, VH4004280: Time to Maximum Observed Plasma Drug Concentration (Tmax)

    Tmax is a measure of the time required to reach the maximum concentration of the drug.

    Time frame: After dose administration at Day 1

  17. Monotherapy, VH4011499: Tmax

    Tmax is a measure of the time required to reach the maximum concentration of the drug.

    Time frame: After dose administration at Day 1 and Day 6

  18. Monotherapy, VH4004280: Plasma Concentration at Day 11 (C11)

    C11 is defined as the concentration of the drug in plasma at Day 11.

    Time frame: At Day 11

  19. Monotherapy, VH4011499: C11

    C11 is defined as the concentration of the drug in plasma at Day 11.

    Time frame: At Day 11

  20. Monotherapy, VH4004280: Change in Plasma HIV-1 RNA From Baseline

    Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

    Time frame: At Baseline (Day 1) and Day 11

  21. Monotherapy, VH4011499: Change in Plasma HIV-1 RNA From Baseline

    Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

    Time frame: At Baseline (Day 1) and Day 11

07

Results

Posted Sep 30, 2025

Participant flow

Monotherapy (Day 1-Day 11)
Participant flow — Monotherapy (Day 1-Day 11)
MilestonePart 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280Part 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499
Started66637673
Completed66637673
Not completed00000000
Follow-Up (Day 11-Day 39)
Participant flow — Follow-Up (Day 11-Day 39)
MilestonePart 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280Part 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499
Started66637673
Completed66637672
Not completed00000001
Withdrew: Withdrawal by subject00000001

Outcome measures

PrimaryMonotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10

Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. Maximum change from baseline was calculated by subtracting the baseline value from the post-dose visit value when the plasma HIV-1 RNA reached its minimum level up to Day 11 (inclusive). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. The results were expressed as log10 copies per milliliter (log10 c/mL).

Time frame:
From Baseline (Day 1) and up to Day 11
Reported as:
Mean · log10 c/mL
Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10
log10 c/mLPart 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280
Baseline (Day 1)5.004 ± 0.45924.923 ± 0.54284.866 ± 0.76964.636 ± 0.6641
Maximum change compared to Baseline (Day 1)-1.056 ± 0.4567-1.391 ± 0.6986-1.983 ± 0.2171-0.070 ± 0.0574
PrimaryMonotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10

Plasma samples were collected for quantitative analysis of plasma HIV-1 RNA. Maximum change from baseline was calculated by subtracting the baseline value from the post-dose visit value when the plasma HIV-1 RNA reached its minimum level up to Day 11 (inclusive). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
From Baseline (Day 1) and up to Day 11
Reported as:
Mean · log10 c/mL
Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10
log10 c/mLPart 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499
Baseline (Day 1)5.001 ± 0.73044.339 ± 0.61854.960 ± 0.72884.714 ± 0.7736
Maximum change compared to Baseline (Day 1)-1.834 ± 0.5141-1.797 ± 0.4544-2.165 ± 0.4310-0.176 ± 0.1969
SecondaryMonotherapy: Number of Participants With Any Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any = occurrence of the event regardless of intensity grade or relation to the study intervention.

Time frame:
From Baseline (Day 1) and up to Day 11
Reported as:
Count of participants · Participants
Monotherapy: Number of Participants With Any Adverse Events (AEs)
ParticipantsPart 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280Part 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499
Monotherapy: Number of Participants With Any Adverse Events (AEs)32222421
SecondaryFollow-up: Number of Participants With Any AEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any = occurrence of the event regardless of intensity grade or relation to the study intervention.

Time frame:
From Day 11 and up to Day 39
Reported as:
Count of participants · Participants
Follow-up: Number of Participants With Any AEs
ParticipantsPart 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280Part 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499
Follow-up: Number of Participants With Any AEs13413350
SecondaryMonotherapy: Number of Participants With AEs by Severity

Severity was rated according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.

Time frame:
From Baseline (Day 1) and up to Day 11
Reported as:
Count of participants · Participants
Monotherapy: Number of Participants With AEs by Severity
ParticipantsPart 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280Part 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499
Grade 102111321
Grade 230111100
Grade 300000000
Grade 400000000
Grade 500000000
SecondaryFollow-up: Number of Participants With AEs by Severity

Severity was rated according to the DAIDS grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.

Time frame:
From Day 11 and up to Day 39
Reported as:
Count of participants · Participants
Follow-up: Number of Participants With AEs by Severity
ParticipantsPart 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280Part 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499
Grade 111102120
Grade 201311230
Grade 301000000
Grade 400000000
Grade 500000000
SecondaryMonotherapy: Number of Participants With AEs Leading to Study Treatment Discontinuation

'Discontinuation' of study intervention refers to any participant who has not received all planned doses of study intervention.

Time frame:
From Baseline (Day 1) and up to Day 11
Reported as:
Count of participants · Participants
Monotherapy: Number of Participants With AEs Leading to Study Treatment Discontinuation
ParticipantsPart 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280Part 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499
Monotherapy: Number of Participants With AEs Leading to Study Treatment Discontinuation————0000
SecondaryMonotherapy and Follow-up, VH4004280: Change From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin

Change from Baseline values for liver panel laboratory parameters total bilirubin and direct bilirubin were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.Standard deviation (SD) = 0.0000 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.0000.

Time frame:
At Baseline (Day 1) and at Days 2, 4, 6, 7, 9, 11, 18, 25, 32 and 39
Reported as:
Mean · Micromole per liter (µmol/L)
Monotherapy and Follow-up, VH4004280: Change From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin
Micromole per liter (µmol/L)Part 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280
Total Bilirubin, Baseline (Day 1)6.641 ± 1.51578.408 ± 5.53836.926 ± 4.63006.783 ± 1.2370
Total Bilirubin, Day 2-0.143 ± 1.7719-0.513 ± 2.96970.239 ± 4.48141.995 ± 3.5100
Total Bilirubin, Day 40.547 ± 1.0073-2.081 ± 3.56141.984 ± 3.1078-1.767 ± 1.5516
Total Bilirubin, Day 6-0.171 ± 3.57710.485 ± 3.60552.366 ± 5.27552.565 ± 2.8460
Total Bilirubin, Day 71.539 ± 1.43070.941 ± 3.32950.599 ± 2.47741.767 ± 3.2189
Total Bilirubin, Day 91.060 ± 2.52300.656 ± 4.25841.055 ± 1.77520.969 ± 3.7672
Total Bilirubin, Day 111.154 ± 1.57581.539 ± 1.86700.085 ± 1.2649-0.171 ± 2.7360
Total Bilirubin, Day 180.684 ± 2.65130.399 ± 2.4005-1.340 ± 3.2199-0.342 ± 1.8016
Total Bilirubin, Day 250.570 ± 1.17310.513 ± 3.0049-2.195 ± 3.5417-0.741 ± 2.2771
Total Bilirubin, Day 320.770 ± 2.1596-0.542 ± 2.5557-1.881 ± 3.47091.026 ± 3.6194
Total Bilirubin, Day 390.923 ± 1.3712-1.197 ± 3.2910-0.513 ± 3.23320.456 ± 2.8682
Direct Bilirubin, Baseline (Day 1)3.410 ± 0.00003.410 ± 0.00003.410 ± 0.00003.410 ± 0.0000
Direct Bilirubin, Day 20.000 ± 0.00000.002 ± 0.00410.000 ± 0.00000.000 ± 0.0000
Direct Bilirubin, Day 40.000 ± 0.00000.000 ± 0.00000.002 ± 0.00410.000 ± 0.0000
Direct Bilirubin, Day 60.000 ± 0.00000.030 ± 0.07390.030 ± 0.07390.000 ± 0.0000
Direct Bilirubin, Day 70.000 ± 0.00000.059 ± 0.14370.000 ± 0.00000.000 ± 0.0000
Direct Bilirubin, Day 90.000 ± 0.00000.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
Direct Bilirubin, Day 110.000 ± 0.00000.002 ± 0.00410.000 ± 0.00000.000 ± 0.0000
Direct Bilirubin, Day 180.000 ± 0.00000.174 ± 0.42210.000 ± 0.00000.000 ± 0.0000
Direct Bilirubin, Day 250.000 ± 0.00000.030 ± 0.07390.000 ± 0.00000.000 ± 0.0000
Direct Bilirubin, Day 320.000 ± 0.00000.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
Direct Bilirubin, Day 390.000 ± 0.00000.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
SecondaryMonotherapy and Follow-up, VH4011499: Change From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin

Change from Baseline values for liver panel laboratory parameters total bilirubin and direct bilirubin were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value. SD = 0.0000 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.0000.

Time frame:
At Baseline (Day 1) and at Days 2, 4, 6, 7, 9, 11, 18, 25, 32 and 39
Reported as:
Mean · µmol/L
Monotherapy and Follow-up, VH4011499: Change From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin
µmol/LPart 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499
Total Bilirubin, Baseline (Day 1)5.643 ± 2.48987.524 ± 2.65794.544 ± 1.75767.011 ± 2.2361
Total Bilirubin, Day 2-0.928 ± 0.90950.114 ± 0.99510.611 ± 1.6008-0.855 ± 0.6165
Total Bilirubin, Day 40.122 ± 2.3975-0.656 ± 0.99371.808 ± 2.3463-0.570 ± 1.5516
Total Bilirubin, Day 6-0.171 ± 2.4741-1.967 ± 2.62860.440 ± 1.4370-2.109 ± 3.6529
Total Bilirubin, Day 70.366 ± 3.4476-0.200 ± 2.71110.367 ± 1.4081-1.995 ± 3.6569
Total Bilirubin, Day 9-0.440 ± 2.3774-0.228 ± 1.40041.099 ± 1.48040.912 ± 3.5924
Total Bilirubin, Day 111.050 ± 2.0766-0.884 ± 1.34390.709 ± 2.3036-2.964 ± 1.2370
Total Bilirubin, Day 18-0.366 ± 2.7081-0.057 ± 1.79890.586 ± 1.77391.083 ± 3.4427
Total Bilirubin, Day 250.366 ± 3.90240.798 ± 3.22581.295 ± 2.1332-1.026 ± 3.0059
Total Bilirubin, Day 320.599 ± 2.91750.513 ± 3.30171.075 ± 2.23980.627 ± 4.9452
Total Bilirubin, Day 390.239 ± 1.3927-0.599 ± 1.78610.489 ± 2.2630-0.855 ± 0.2418
Direct Bilirubin, Baseline (Day 1)3.485 ± 0.19773.410 ± 0.00003.705 ± 0.77943.527 ± 0.2032
Direct Bilirubin, Day 2-0.075 ± 0.19770.000 ± 0.0000-0.295 ± 0.7794-0.117 ± 0.2032
Direct Bilirubin, Day 4-0.057 ± 0.13960.000 ± 0.0000-0.295 ± 0.7794-0.114 ± 0.1975
Direct Bilirubin, Day 6-0.073 ± 0.19390.000 ± 0.0000-0.295 ± 0.7794-0.117 ± 0.2032
Direct Bilirubin, Day 7-0.049 ± 0.21970.000 ± 0.0000-0.295 ± 0.77941.140 ± 2.2862
Direct Bilirubin, Day 9-0.075 ± 0.19770.002 ± 0.0041-0.295 ± 0.7794-0.057 ± 0.0987
Direct Bilirubin, Day 11-0.073 ± 0.19830.000 ± 0.0000-0.295 ± 0.7794-0.117 ± 0.2032
Direct Bilirubin, Day 18-0.075 ± 0.19770.000 ± 0.0000-0.295 ± 0.77940.057 ± 0.0987
Direct Bilirubin, Day 250.027 ± 0.15710.030 ± 0.0739-0.295 ± 0.7794-0.114 ± 0.1975
Direct Bilirubin, Day 32-0.057 ± 0.23950.230 ± 0.5626-0.295 ± 0.77940.114 ± 0.1975
Direct Bilirubin, Day 39-0.087 ± 0.21350.000 ± 0.0000-0.295 ± 0.7794-0.171 ± 0.2418
SecondaryMonotherapy and Follow-up, VH4004280: Change From Baseline for Liver Panel Laboratory Parameters - Alanine Aminotransferace (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)

Change from Baseline values for liver panel laboratory parameters ALT, ALP and AST were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

Time frame:
At Baseline (Day 1) and at Days 2, 4, 6, 7, 9, 11, 18, 25, 32 and 39
Reported as:
Mean · International units per liter (IU/L)
Monotherapy and Follow-up, VH4004280: Change From Baseline for Liver Panel Laboratory Parameters - Alanine Aminotransferace (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)
International units per liter (IU/L)Part 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280
ALT, Baseline (Day 1)31.3 ± 13.5921.7 ± 7.1733.2 ± 13.2352.7 ± 55.82
ALT, Day 2-2.8 ± 3.25-1.8 ± 3.25-0.2 ± 3.5615.0 ± 29.46
ALT, Day 4-3.8 ± 4.09-2.3 ± 2.800.2 ± 6.104.7 ± 9.29
ALT, Day 6-7.8 ± 9.33-1.3 ± 1.512.2 ± 8.13-13.7 ± 27.14
ALT, Day 7-6.7 ± 9.77-2.0 ± 3.030.2 ± 7.39-19.3 ± 32.62
ALT, Day 9-6.0 ± 13.69-0.7 ± 9.631.5 ± 12.10-20.7 ± 35.81
ALT, Day 11-8.8 ± 15.78-2.0 ± 6.26-0.2 ± 11.99-16.7 ± 29.74
ALT, Day 18-6.2 ± 14.16-0.2 ± 4.458.3 ± 27.46-15.7 ± 31.18
ALT, Day 25-6.8 ± 15.48-0.5 ± 2.171.7 ± 14.54-27.7 ± 44.50
ALT, Day 32-9.2 ± 11.97-0.3 ± 4.230.3 ± 12.32-33.0 ± 56.40
ALT, Day 39-9.8 ± 11.12-0.3 ± 3.50-4.0 ± 8.72-33.0 ± 54.62
ALP, Baseline (Day 1)79.2 ± 14.4074.3 ± 15.7471.7 ± 19.3964.3 ± 16.80
ALP, Day 2-1.3 ± 7.87-2.7 ± 10.03-1.0 ± 3.16-3.0 ± 3.00
ALP, Day 40.6 ± 5.41-5.0 ± 5.90-2.6 ± 2.51-1.0 ± 3.61
ALP, Day 61.5 ± 6.75-4.5 ± 6.350.7 ± 5.35-2.3 ± 1.15
ALP, Day 7-0.2 ± 6.24-6.2 ± 2.71-2.0 ± 4.52-6.0 ± 4.36
ALP, Day 9-0.2 ± 2.95-4.3 ± 6.09-3.5 ± 5.82-6.3 ± 6.66
ALP, Day 11-5.0 ± 2.94-4.8 ± 6.05-5.8 ± 8.28-6.3 ± 4.93
ALP, Day 18-0.5 ± 3.33-7.0 ± 5.40-2.7 ± 8.50-4.3 ± 4.51
ALP, Day 251.0 ± 11.17-5.0 ± 4.69-1.3 ± 8.71-5.0 ± 4.36
ALP, Day 323.2 ± 21.10-2.7 ± 10.84-3.8 ± 8.47-5.3 ± 5.77
ALP, Day 390.6 ± 4.16-5.5 ± 7.82-2.2 ± 4.150.3 ± 3.51
AST, Baseline (Day 1)26.0 ± 4.9421.5 ± 4.2327.2 ± 3.4929.7 ± 11.72
AST, Day 2-3.5 ± 3.62-0.8 ± 2.71-0.2 ± 4.0911.0 ± 26.00
AST, Day 4-3.6 ± 3.21-0.8 ± 0.750.8 ± 3.96-1.0 ± 5.29
AST, Day 6-4.8 ± 4.36-2.0 ± 1.260.7 ± 5.54-8.3 ± 11.06
AST, Day 7-4.8 ± 4.54-2.2 ± 2.23-1.2 ± 4.88-9.0 ± 9.85
AST, Day 9-5.0 ± 6.00-1.5 ± 4.722.5 ± 8.53-9.3 ± 10.69
AST, Day 11-6.3 ± 6.34-2.0 ± 4.607.0 ± 22.52-6.7 ± 5.03
AST, Day 18-4.7 ± 6.440.0 ± 6.514.2 ± 16.46-1.0 ± 3.61
AST, Day 25-4.7 ± 9.35-0.3 ± 3.561.5 ± 7.40-11.3 ± 11.93
AST, Day 32-5.0 ± 6.81-1.3 ± 3.080.7 ± 4.72-9.0 ± 14.80
AST, Day 39-6.6 ± 5.500.5 ± 3.39-2.4 ± 3.13-10.3 ± 13.65
SecondaryMonotherapy and Follow-up, VH4011499: Change From Baseline for Liver Panel Laboratory Parameters - ALT, ALP and AST

Change from Baseline values for liver panel laboratory parameters ALT, ALP and AST were summarised. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

Time frame:
At Baseline (Day 1) and at Days 2, 4, 6, 7, 9, 11, 18, 25, 32 and 39
Reported as:
Mean · IU/L
Monotherapy and Follow-up, VH4011499: Change From Baseline for Liver Panel Laboratory Parameters - ALT, ALP and AST
IU/LPart 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499
ALT, Baseline (Day 1)14.9 ± 4.4119.5 ± 9.0331.7 ± 22.6018.3 ± 2.08
ALT, Day 21.7 ± 1.25-1.2 ± 1.83-1.6 ± 3.780.7 ± 0.58
ALT, Day 42.4 ± 1.72-1.0 ± 3.85-3.6 ± 13.20-1.0 ± 1.00
ALT, Day 6-0.1 ± 1.57-1.2 ± 3.76-5.1 ± 14.580.7 ± 1.15
ALT, Day 70.1 ± 2.54-1.5 ± 4.76-7.3 ± 14.91-0.7 ± 1.57
ALT, Day 9-0.3 ± 1.98-0.2 ± 4.07-8.0 ± 16.42-0.3 ± 2.08
ALT, Day 110.0 ± 3.32-1.2 ± 3.76-7.3 ± 11.710.0 ± 3.61
ALT, Day 180.3 ± 5.19-1.3 ± 4.46-4.0 ± 17.911.7 ± 2.52
ALT, Day 252.0 ± 9.020.0 ± 5.66-7.4 ± 17.520.7 ± 0.58
ALT, Day 324.0 ± 13.62-2.7 ± 3.88-10.3 ± 16.633.0 ± 4.36
ALT, Day 390.0 ± 7.840.8 ± 4.49-3.6 ± 15.8728.0 ± 28.28
ALP, Baseline (Day 1)81.1 ± 14.5568.2 ± 18.9078.9 ± 20.6989.3 ± 16.50
ALP, Day 21.0 ± 5.60-1.2 ± 2.480.6 ± 6.48-0.3 ± 1.53
ALP, Day 42.7 ± 6.97-2.5 ± 3.33-4.9 ± 13.38-0.7 ± 7.51
ALP, Day 6-1.4 ± 7.44-3.7 ± 5.75-3.6 ± 4.696.3 ± 8.33
ALP, Day 73.9 ± 5.70-4.5 ± 3.39-0.4 ± 8.664.0 ± 8.72
ALP, Day 90.0 ± 9.80-1.5 ± 1.76-1.4 ± 9.76-0.7 ± 8.08
ALP, Day 112.9 ± 13.32-1.3 ± 3.20-1.6 ± 7.9610.3 ± 14.47
ALP, Day 18-0.1 ± 6.01-3.2 ± 3.92-2.9 ± 6.492.3 ± 9.71
ALP, Day 252.4 ± 7.59-5.0 ± 5.76-6.4 ± 10.97-1.7 ± 17.21
ALP, Day 320.3 ± 9.05-4.5 ± 3.45-3.7 ± 9.81-2.3 ± 8.02
ALP, Day 39-2.4 ± 13.72-2.2 ± 8.04-1.7 ± 14.691.0 ± 11.31
AST, Baseline (Day 1)18.6 ± 3.8724.0 ± 8.0724.7 ± 7.2027.7 ± 5.51
AST, Day 2-0.7 ± 2.43-2.3 ± 2.80-2.0 ± 1.29-2.3 ± 3.21
AST, Day 41.1 ± 4.45-2.7 ± 3.271.7 ± 7.50-2.3 ± 0.58
AST, Day 6-0.9 ± 4.02-1.5 ± 5.68-2.4 ± 3.55-1.7 ± 3.21
AST, Day 7-1.7 ± 4.07-3.5 ± 5.75-3.7 ± 5.12-5.7 ± 2.31
AST, Day 90.0 ± 3.00-2.7 ± 4.41-4.3 ± 5.02-5.0 ± 6.24
AST, Day 11-1.6 ± 3.74-2.2 ± 4.79-2.1 ± 3.29-4.7 ± 7.51
AST, Day 18-1.3 ± 5.82-3.2 ± 5.312.4 ± 9.55-0.3 ± 5.51
AST, Day 251.6 ± 5.86-0.5 ± 4.32-2.6 ± 4.86-3.7 ± 0.58
AST, Day 322.8 ± 9.97-1.4 ± 3.13-2.9 ± 6.69-2.3 ± 4.93
AST, Day 390.0 ± 5.431.3 ± 2.581.7 ± 10.6423.0 ± 5.66
SecondaryMonotherapy and Follow-up, VH4004280: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin

Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.

Time frame:
From Baseline (Day 1) and up to Day 39
Reported as:
Count of participants · Participants
Monotherapy and Follow-up, VH4004280: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin
ParticipantsPart 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280
Total Bilirubin, Increase to Grade 10100
Total Bilirubin, Increase to Grade 20000
Total Bilirubin, Increase to Grade 30000
Total Bilirubin, Increase to Grade 40000
Direct Bilirubin, Increase to Grade 10000
Direct Bilirubin, Increase to Grade 20000
Direct Bilirubin, Increase to Grade 30000
Direct Bilirubin, Increase to Grade 40000
SecondaryMonotherapy and Follow-up, VH4011499: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin

Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.

Time frame:
From Baseline (Day 1) and up to Day 39
Reported as:
Count of participants · Participants
Monotherapy and Follow-up, VH4011499: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - Total Bilirubin and Direct Bilirubin
ParticipantsPart 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499
Total Bilirubin, Increase to Grade 10000
Total Bilirubin, Increase to Grade 20000
Total Bilirubin, Increase to Grade 30000
Total Bilirubin, Increase to Grade 40000
Direct Bilirubin, Increase to Grade 10000
Direct Bilirubin, Increase to Grade 20000
Direct Bilirubin, Increase to Grade 30001
Direct Bilirubin, Increase to Grade 40000
SecondaryMonotherapy and Follow-up, VH4004280: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - ALT, ALP and AST

Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.

Time frame:
From Baseline (Day 1) and up to Day 39
Reported as:
Count of participants · Participants
Monotherapy and Follow-up, VH4004280: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - ALT, ALP and AST
ParticipantsPart 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280
ALT, Increase to Grade 11010
ALT, Increase to Grade 20010
ALT, Increase to Grade 30000
ALT, Increase to Grade 40000
ALP, Increase to Grade 10000
ALP, Increase to Grade 20000
ALP, Increase to Grade 30000
ALP, Increase to Grade 40000
AST, Increase to Grade 11011
AST, Increase to Grade 20000
AST, Increase to Grade 30000
AST, Increase to Grade 40000
SecondaryMonotherapy and Follow-up, VH4011499: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - ALT, ALP and AST

Laboratory abnormalities were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences.

Time frame:
From Baseline (Day 1) and up to Day 39
Reported as:
Count of participants · Participants
Monotherapy and Follow-up, VH4011499: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Laboratory Parameters - ALT, ALP and AST
ParticipantsPart 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499
ALT, Increase to Grade 10011
ALT, Increase to Grade 20000
ALT, Increase to Grade 30000
ALT, Increase to Grade 40000
ALP, Increase to Grade 10000
ALP, Increase to Grade 20000
ALP, Increase to Grade 30000
ALP, Increase to Grade 40000
AST, Increase to Grade 10001
AST, Increase to Grade 20000
AST, Increase to Grade 30000
AST, Increase to Grade 40000
SecondaryMonotherapy, VH4004280: Maximum Observed Plasma Drug Concentration (Cmax)

Cmax is defined as the maximum concentration of the drug in plasma.

Time frame:
After dose administration at Day 1
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Monotherapy, VH4004280: Maximum Observed Plasma Drug Concentration (Cmax)
Nanogram per milliliter (ng/mL)Part 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified Dose
Monotherapy, VH4004280: Maximum Observed Plasma Drug Concentration (Cmax)131.57 ± 77.68364.70 ± 85.21473.00 ± 54.23
SecondaryMonotherapy, VH4011499: Cmax

Cmax is defined as the maximum concentration of the drug in plasma.

Time frame:
After dose administration at Day 1 and Day 6
Reported as:
Geometric mean · ng/mL
Monotherapy, VH4011499: Cmax
ng/mLPart 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified Dose
Day 127.63 ± 94.5331.88 ± 26.58133.59 ± 42.34
Day 635.30 ± 81.3132.31 ± 25.97141.18 ± 47.79
SecondaryMonotherapy, VH4004280: Time to Maximum Observed Plasma Drug Concentration (Tmax)

Tmax is a measure of the time required to reach the maximum concentration of the drug.

Time frame:
After dose administration at Day 1
Reported as:
Median · Hour (h)
Monotherapy, VH4004280: Time to Maximum Observed Plasma Drug Concentration (Tmax)
Hour (h)Part 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified Dose
Monotherapy, VH4004280: Time to Maximum Observed Plasma Drug Concentration (Tmax)7.95 (6.0 to 9.7)9.00 (6.0 to 11.6)8.04 (6.0 to 10.0)
SecondaryMonotherapy, VH4011499: Tmax

Tmax is a measure of the time required to reach the maximum concentration of the drug.

Time frame:
After dose administration at Day 1 and Day 6
Reported as:
Median · h
Monotherapy, VH4011499: Tmax
hPart 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified Dose
Day 19.95 (6.0 to 12.0)9.88 (8.1 to 10.1)8.00 (4.1 to 12.0)
Day 610.00 (8.0 to 26.9)10.04 (8.0 to 11.6)11.52 (6.0 to 24.1)
SecondaryMonotherapy, VH4004280: Plasma Concentration at Day 11 (C11)

C11 is defined as the concentration of the drug in plasma at Day 11.

Time frame:
At Day 11
Reported as:
Geometric mean · ng/mL
Monotherapy, VH4004280: Plasma Concentration at Day 11 (C11)
ng/mLPart 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified Dose
Monotherapy, VH4004280: Plasma Concentration at Day 11 (C11)18.07 ± 132.0748.53 ± 130.3350.42 ± 41.52
SecondaryMonotherapy, VH4011499: C11

C11 is defined as the concentration of the drug in plasma at Day 11.

Time frame:
At Day 11
Reported as:
Geometric mean · ng/mL
Monotherapy, VH4011499: C11
ng/mLPart 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified Dose
Monotherapy, VH4011499: C1111.16 ± 50.0210.56 ± 36.6127.04 ± 50.68
SecondaryMonotherapy, VH4004280: Change in Plasma HIV-1 RNA From Baseline

Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

Time frame:
At Baseline (Day 1) and Day 11
Reported as:
Mean · log10 c/mL
Monotherapy, VH4004280: Change in Plasma HIV-1 RNA From Baseline
log10 c/mLPart 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified Dose
Baseline (Day 1)5.004 ± 0.45924.923 ± 0.54284.866 ± 0.7696
Day 11-0.941 ± 0.6608-1.322 ± 0.7727-1.939 ± 0.1124
SecondaryMonotherapy, VH4011499: Change in Plasma HIV-1 RNA From Baseline

Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

Time frame:
At Baseline (Day 1) and Day 11
Reported as:
Mean · log10 c/mL
Monotherapy, VH4011499: Change in Plasma HIV-1 RNA From Baseline
log10 c/mLPart 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified Dose
Baseline (Day 1)5.001 ± 0.73044.339 ± 0.61854.960 ± 0.7288
Day 11-1.801 ± 0.5165-1.750 ± 0.4962-2.165 ± 0.4310

Adverse events

Collected over All-cause mortality, SAEs and non-serious AEs (including solicited and unsolicited events) were assessed from Day 1 [Monotherapy Phase] and up to Day 39 [Follow-up Phase].. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1a: VH4004280 Dose Level 1 (Monotherapy)0/6 (0%)0/6 (0%)3/6 (50%)
Part 1a: VH4004280 Dose Level 20/6 (0%)0/6 (0%)2/6 (33.3%)
Part 2a: VH4004280 Pre-specified Dose (Monotherapy)0/6 (0%)0/6 (0%)2/6 (33.3%)
Matching Placebo for VH4004280 (Monotherapy)0/3 (0%)0/3 (0%)2/3 (66.7%)
Part 1b: VH4011499 Dose Level 1 (Monotherapy)0/7 (0%)0/7 (0%)2/7 (28.6%)
Part 1b: VH4011499 Dose Level 2 (Monotherapy)0/6 (0%)0/6 (0%)4/6 (66.7%)
Part 2b: VH4011499 Pre-specified Dose (Monotherapy)0/7 (0%)0/7 (0%)2/7 (28.6%)
Matching Placebo for VH4011499 (Monotherapy)0/3 (0%)0/3 (0%)1/3 (33.3%)
Part 1a: VH4004280 Dose Level 1 (Follow-up)0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1a: VH4004280 Dose Level 2 (Follow-up)0/6 (0%)0/6 (0%)3/6 (50%)
Part 2a: VH4004280 Pre-specified Dose (Follow-up)0/6 (0%)0/6 (0%)4/6 (66.7%)
Matching Placebo for VH4004280 (Follow-up)0/3 (0%)0/3 (0%)1/3 (33.3%)
Part 1b: VH4011499 Dose Level 1 (Follow-up)0/7 (0%)0/7 (0%)3/7 (42.9%)
Part 1b: VH4011499 Dose Level 2 (Follow-up)0/6 (0%)0/6 (0%)3/6 (50%)
Part 2b: VH4011499 Pre-specified Dose (Follow-up)0/7 (0%)0/7 (0%)5/7 (71.4%)
Matching Placebo for VH4011499 (Follow-up)0/3 (0%)0/3 (0%)0/3 (0%)
Most frequent other events
Showing 10 of 43
Most frequent other events
EventPart 1a: VH4004280 Dose Level 1 (Monotherapy)Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified Dose (Monotherapy)Matching Placebo for VH4004280 (Monotherapy)Part 1b: VH4011499 Dose Level 1 (Monotherapy)Part 1b: VH4011499 Dose Level 2 (Monotherapy)Part 2b: VH4011499 Pre-specified Dose (Monotherapy)Matching Placebo for VH4011499 (Monotherapy)Part 1a: VH4004280 Dose Level 1 (Follow-up)Part 1a: VH4004280 Dose Level 2 (Follow-up)Part 2a: VH4004280 Pre-specified Dose (Follow-up)Matching Placebo for VH4004280 (Follow-up)Part 1b: VH4011499 Dose Level 1 (Follow-up)Part 1b: VH4011499 Dose Level 2 (Follow-up)Part 2b: VH4011499 Pre-specified Dose (Follow-up)Matching Placebo for VH4011499 (Follow-up)
Vessel puncture site haematomaGeneral disorders0/60/60/61/30/71/62/70/30/60/60/60/30/70/60/70/3
Drug hypersensitivityImmune system disorders0/60/60/60/30/70/60/71/30/60/60/60/30/70/60/70/3
Genital herpesInfections and infestations0/60/60/60/30/70/60/70/30/60/60/61/30/70/60/70/3
InfluenzaInfections and infestations0/60/60/60/30/70/60/70/30/60/60/61/31/70/60/70/3
Blood creatinine increasedInvestigations0/62/60/60/30/70/60/70/30/62/60/60/30/70/60/70/3
Transaminases increasedInvestigations0/60/60/61/30/70/60/70/31/60/60/60/30/70/61/70/3
HypertriglyceridaemiaMetabolism and nutrition disorders0/60/60/60/30/70/60/70/30/62/60/60/30/70/60/70/3
Back painMusculoskeletal and connective tissue disorders0/60/60/60/30/70/60/71/30/60/60/60/30/70/60/70/3
HeadacheNervous system disorders1/60/60/60/31/71/61/71/30/60/60/60/30/70/60/70/3
NauseaGastrointestinal disorders0/60/60/60/30/70/60/70/30/60/60/60/30/70/62/70/3

Baseline characteristics

Baseline measures are presented based on Exposed population, which included all participants that received a study intervention.

Age, Continuous
Age, Continuous(YEARS)Part 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280Part 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499Total
Mean34.3 ± 12.8242.8 ± 10.331.5 ± 9.7528.7 ± 9.2931.6 ± 9.2949.3 ± 7.4528.6 ± 9.9326 ± 2.6534.8 ± 11.6
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Part 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280Part 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499Total
Male5562736337
Female110103107
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1a: VH4004280 Dose Level 1Part 1a: VH4004280 Dose Level 2Part 2a: VH4004280 Pre-specified DoseMatching Placebo for VH4004280Part 1b: VH4011499 Dose Level 1Part 1b: VH4011499 Dose Level 2Part 2b: VH4011499 Pre-specified DoseMatching Placebo for VH4011499Total
American Indian or Alaska Native000000404
Black or African American122003019
White5443733231
08

Study locations

20 sites
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Newark, New Jersey 07102, United States
  • GSK Investigational Site
    Buenos Aires, 1023, Argentina
  • GSK Investigational Site
    Buenos Aires, C1202ABB, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425AGC, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Bueno, C1405CKC, Argentina
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • GSK Investigational Site
    Marseille, 13003, France
  • GSK Investigational Site
    Nantes, 44093, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Cologne, 50937, Germany
  • GSK Investigational Site
    Milan, 20157, Italy
  • GSK Investigational Site
    Guadalajara, 44160, Mexico
  • GSK Investigational Site
    Mexico City, 06760, Mexico
  • GSK Investigational Site
    Barcelona, 08907, Spain
  • GSK Investigational Site
    Barcelona, 08916, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    London, SE5 8RX, United Kingdom
09

References and documents

Publications

  • Griesel R, Nunez SA, Cordova E, Perez Rios AM, Ridilenir VL, Lehmann C, Slim J, Arenzana CB, Szabo J, Cahn P, Post FA, Pierce A, Pestrak M, Jeffrey JL, Thakkar N, Shepherd B, Bainbridge V, Angelis K, McMillan C, Benn P. Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial. Clin Infect Dis. 2026 Jul 29:ciag452. doi: 10.1093/cid/ciag452. Online ahead of print. PubMed 42525562 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to: https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jun 2024, 7 months.

Results were first posted in Sep 2025, 1 year 3 months after primary completion.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 7 months is below that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2023
First posted
Sep 15, 2023
StartActual
Oct 25, 2023
Primary completionActual
Jun 24, 2024
CompletionActual
Jun 24, 2024
Results first posted
Sep 30, 2025
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06039579
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Sep 15, 2023
Start date
Oct 25, 2023
Primary completion
Jun 24, 2024
Completion
Jun 24, 2024
Results posted
Sep 30, 2025
Last update
Sep 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: VH4004280 · Dezecapavir

Start the discussion